Symphogen

Symphogen

Symphogen

Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use. The Europeanbased company is developing nextgeneration antibody therapeutics for the treatment of cancer.
Founded
2000
Raised
$495.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$76,630,962
Debt financing - 2015
$53,767,400
Private equity - 2013
Team Size
50+
Employees
FinSMEs

Servier Closes Purchase of Symphogen